B cell depletion may lead to normalization of anti-platelet,anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus
- 1 January 2004
- journal article
- case report
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 92 (11), 1150-1153
- https://doi.org/10.1055/s-0037-1614293
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapyLupus, 2003
- Remission of refractory lupus nephritis with a protocol including rituximab.Lupus, 2003
- Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosusRheumatology, 2003
- Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapyArthritis & Rheumatism, 2003
- Treatment of IgM antibody associated polyneuropathies using rituximabJournal of Neurology, Neurosurgery & Psychiatry, 2003
- An open study of B lymphocyte depletion in systemic lupus erythematosusArthritis & Rheumatism, 2002
- Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapyArthritis & Rheumatism, 2001
- Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpuraBlood, 2001
- Rituximab for myasthenia gravis developing after bone marrow transplantNeurology, 2000
- Humoral Immunity Due to Long-Lived Plasma CellsImmunity, 1998